CCL3L1: A Promising Drug Target and Biomarker for Small-Inducible Cytokine A3-Like 1

Target Name: CCL3L1

NCBI ID: G6349

CCL3L1: A Promising Drug Target and Biomarker for Small-Inducible Cytokine A3-Like 1

Abstract:

Small-inducible cytokine A3-like 1 (CCL3L1) has been shown to play a crucial role in various physiological processes. However, its exact function and the underlying mechanisms that regulate its levels have remained unresolved. This article aims to provide an overview of CCL3L1, including its structure, function, and potential as a drug target and biomarker.

Introduction:

The cytokine system is a complex network of cytokines and their target cells that play a crucial role in maintaining the balance of the immune system and regulating various physiological processes. One of the key cytokines involved in this system is CCL3L1, also known as small-inducible cytokine A3-like 1. CCL3L1 is a 24-kDa cytokine that is expressed in various tissues and cells, including macrophages, dendritic cells, and epithelial cells. It has been shown to play a role in various physiological processes, including immune regulation, inflammation, and tissue repair.

Structure and Function:

The structure of CCL3L1 is well conserved in various species, and its primary structure is characterized by a single open reading frame containing a cytoplasmic tail, a transmembrane region, and an extracellular domain. The cytoplasmic tail of CCL3L1 consists of a single amino acid residue, which is often used as a calibrator to measure the activity of the cytokine in cell culture.

The function of CCL3L1 is regulated by various intracellular signaling pathways, including the TGF-β pathway, the NF-kappa-B pathway, and the PI3K/AKT pathway. CCL3L1 has been shown to play a role in the regulation of immune cell function, including the development and activation of natural killer cells, B cells, and T cells. It has also been shown to play a role in the regulation of inflammation, including the regulation of the inflammatory response and the control of inflammation-induced tissue damage.

In addition to its role in immune and inflammatory regulation, CCL3L1 has also been shown to play a role in cell survival and metabolism. CCL3L1 has been shown to promote the growth and survival of various cell types, including cancer cells, and to regulate cell apoptosis.

Drug Target Potential:

The potential drug targeting of CCL3L1 is due to its unique structure and function. CCL3L1 is a cytokine that can be targeted by small molecules, making it an attractive target for drug development. Several studies have shown that small molecules can inhibit the activity of CCL3L1 and enhance its degradation, leading to a decrease in its levels in the cell.

One of the most promising small molecules that has been shown to target CCL3L1 is curcumin, an inhibitor of the nuclear factor kappa B (NFKB) signaling pathway. Curcumin has been shown to inhibit the activity of CCL3L1 and its downstream targets, including nuclear factor kappa B, leading to a decrease in the levels of CCL3L1 in the cell.

Another small molecule that has been shown to target CCL3L1 is 2-methoxybenzone (2-MB), a potent inhibitor of the aryl hydrocarbon receptor (ARH), which is a G protein-coupled receptor that is involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

Biomarker Potential:

The potential use of CCL3L1 as a biomarker for various diseases has been evaluated in several studies. One of the most promising biomarkers for CCL3L1 is its ability to regulate the expression of several genes involved in cell growth, apoptosis, and inflammation.

For example, several studies have shown that CCL3L1 can

Protein Name: C-C Motif Chemokine Ligand 3 Like 1

Functions: Chemotactic for lymphocytes and monocytes. Is a ligand for CCR1, CCR3 and CCR5. Is an inhibitor of HIV-1-infection. The processed form LD78-beta(3-70) shows a 20-fold to 30-fold higher chemotactic activity and is a very potent inhibitor of HIV-1-infection. LD78-beta(3-70) is also a ligand for CCR1, CCR3 and CCR5

More Common Targets